Evidence map›Paper›PMID 39920484›Full record

ArticleMolecular biomedicine2025

Performance of urine DNA Neuritin 1 methylation test for urothelial carcinoma detection.

Yucai Wu, Yanqing Gong, Liqun Zhou, Abai Xu, Xuesong Li

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yucai Wu *Department of Urology, Peking University First Hospital, Institute of Urology, Peking University; National Urological Cancer Center; Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, 8 Xishiku Street, Beijing, 100034, China.
Yanqing Gong *Department of Urology, Peking University First Hospital, Institute of Urology, Peking University; National Urological Cancer Center; Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, 8 Xishiku Street, Beijing, 100034, China.
Liqun ZhouDepartment of Urology, Peking University First Hospital, Institute of Urology, Peking University; National Urological Cancer Center; Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, 8 Xishiku Street, Beijing, 100034, China. zhoulqmail@sina.com.
Abai XuDepartment of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China. lc96xab@163.com.
Xuesong LiDepartment of Urology, Peking University First Hospital, Institute of Urology, Peking University; National Urological Cancer Center; Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, 8 Xishiku Street, Beijing, 100034, China. pineneedle@sina.com.

Funding

the Beijing Science and Technology Plan-Capital Clinical Diagnosis and Treatment Technology Research and Demonstration Application Z211100002921070the Capital's Funds for Health Improvement and Research 2022-1-4072the National Key R&D Program of China 2023YFC2507001the National Natural Science Foundation of China 82173216the National Natural Science Foundation of China 82273350
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39920484
PMCPMC11805734

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.